Depakote
(divalproex)ApprovedSmall molecule
AbbVieDepakote is one of 4 small molecule programs targeting Intellectual disability. It is currently in Approved.
2
Indications
20
Total Trials
0
Active Trials
3
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Intellectual Disability
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Glucophage
EMD SeronoApproved
Depakote
AbbVieApproved
Clozaril
LLife Extension Foundation Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bipolar Disorder5 trials
Sequential Multiple Assignment Treatment for Bipolar Disorder
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 4·NCT01588457·112 enrolled
Post-Traumatic Stress Disorder2 trials
Bipolar I Disorder2 trials
Huntington's Disease1 trial
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00095355·35 enrolled
9 more indications
Intermittent Explosive Disorder1 trial
Intellectual disability1 trial
Alzheimer's Disease1 trial
Effect of Lithium and Divalproex in Alzheimer's Disease
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00088387·35 enrolled
Olanzapine1 trial
Regulatory
FDA Approval Timeline[4]
Oct 26, 1984
DEPAKOTE
NDA NDA018723
Sep 12, 1989
DEPAKOTE
NDA NDA019680
Jul 11, 1990
DEPAKOTE CP
NDA NDA019794
May 31, 2002
DEPAKOTE ER
NDA NDA021168
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for divalproex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]